Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720707 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TTRTSHRMEN1KMT2A | |
| Tetrahydrofuran SCHEMBL2360611 | 0.96 | ALDH1A1 (0.67) | ALDH1A1TTRTSHRMEN1KMT2A | |
| SCHEMBL9539378 | 0.96 | ALDH1A1 (0.67) | ALDH1A1TTRTSHRMEN1KMT2A | |
| SCHEMBL9050010 | 0.96 | ALDH1A1 (0.67) | ALDH1A1TTRTSHR | |
| SCHEMBL7758217 | 0.96 | ALDH1A1 (0.67) | ALDH1A1TTRTSHRMEN1KMT2A | |
| Tetrahydrofuran SCHEMBL23573614 | 0.96 | ALDH1A1 (0.67) | ALDH1A1TTRTSHRMEN1KMT2A | |
| SCHEMBL11741977 | 0.96 | ALDH1A1 (0.67) | ALDH1A1TTRTSHR | |
| Dioxane SCHEMBL5598923 | 0.96 | ALDH1A1 (0.67) | ALDH1A1TTRTSHRMEN1KMT2A | |
| SCHEMBL3419841 | 0.92 | ALDH1A1 (0.61) | ALDH1A1TTRTSHR | |
| SCHEMBL1080336 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548496-B2 | Anticancer agents | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | claimed |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | AMERICAN CYANAMID COMPANY | 2002-11-07 | — | — | US | claimed |
| CN-106882820-B | Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2020-05-29 | — | — | CN | disclosed |
| EP-2896612-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-RE42376-E1 | Substituted 3-cyanoquinolines | WYETH HOLDINGS CORPORATION (US) | 2011-05-17 | — | — | US | disclosed |
| EP-1486501-B1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-6548496-B2 | Anticancer agents | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | AMERICAN CYANAMID COMPANY | 2002-11-07 | — | — | US | disclosed |
| US-6432979-B1 | ADMINISTERING SYNERGISTIC MIXTURE OF NON-STEROIDAL ANTIINFLAMMATORY AGENT AND EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR COMPRISING 3-CYANOQUINOLINE DERIVATIVE | AMERICAN CYANAMID COMPANY | 2002-08-13 | — | — | US | disclosed |
| US-6297258-B1 | USEFUL AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE. | AMERICAN CYANAMID COMPANY | 2001-10-02 | — | — | US | disclosed |
| EP-0053023-B1 | HYDROXYLATION OF OLEFINS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4393253-A | Hydroxylation of olefins | EXXON RESEARCH & ENGINEERING CO. (US) | 1983-07-12 | — | — | US | disclosed |
| EP-0053023-A1 | Hydroxylation of olefins | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1982-06-02 | — | — | EP | disclosed |
| US-4314088-A | Hydroxylation of olefins | EXXON RESEARCH & ENGINEERING CO. (US) | 1982-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | GRM1, GRIN1, GRM3 | ALDH1A1 960/4885TTR 4297/4885TSHR 417/4885 |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | ABL1, ROS1, ALK | ALDH1A1 1730/4885TTR 4554/4885TSHR 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.